

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/GB05/001142

International filing date: 18 March 2005 (18.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: GB
Number: 0406215.4
Filing date: 19 March 2004 (19.03.2004)

Date of receipt at the International Bureau: 21 June 2005 (21.06.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



PCT/GB2005/001142



INVESTOR IN PEOPLE


The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.


Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

Dated 14 June 2005

Patents Form 1/77

Patents Act 1977
(Rule 16)**Request for grant of a patent***(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)*19MAR04 E832416-1/002973
P01/7700 8/00-0406215.4 NONE

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

1. Your reference

P104457GB

19 MAR 2004

2. Patent application number

(The Patent Office will fill this part in)

0406215.4

3. Full name, address and postcode of the or of each applicant *(underline all surnames)*Procure Therapeutics Limited
Innovation Centre
York Science Park
YORK
YO10 5DG
GBPatents ADP number *(if you know it)*

If the applicant is a corporate body, give the country/state of its incorporation

England and Wales

8720906001

4. Title of the invention

Prostate Stem Cell

5. Name of your agent *(if you have one)*

Harrison Goddard Foote

"Address for service" in the United Kingdom to which all correspondence should be sent *(including the postcode)*31 St Saviourgate
YORK
YO1 8NQ
GBPatents ADP number *(if you know it)*

14571001-

791423 7002

6. Priority: Complete this section if you are declaring priority from one or more earlier patent applications, filed in the last 12 months.

Country

Priority application number
*(if you know it)*Date of filing
(day / month / year)

7. Divisionals, etc: Complete this section only if this application is a divisional application or resulted from an entitlement dispute (see note f)

Number of earlier UK application

Date of filing
(day / month / year)

8. Is a Patents Form 7/77 (Statement of inventorship and of right to grant of a patent) required in support of this request?

Answer YES if:

- a) any applicant named in part 3 is not an inventor, or
- b) there is an inventor who is not named as an applicant, or
- c) any named applicant is a corporate body.

Otherwise answer NO (See note d)

Yes

Patents Form 1/77

Patents Form 1/77

9. Accompanying documents: A patent application must include a description of the invention. Not counting duplicates, please enter the number of pages of each item accompanying this form:

Continuation sheets of this form

Description 19

Claim(s) 8

Abstract 1

Drawing(s) 2 + 2 fm.

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)


Request for a preliminary examination and search (Patents Form 9/77)

Request for a substantive examination (Patents Form 10/77)

Any other documents (please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)



Date 19.3.04

12. Name, daytime telephone number and e-mail address, if any, of person to contact in the United Kingdom

01904 732120

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered YES in part 8, a Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- Part 7 should only be completed when a divisional application is being made under section 15(4), or when an application is being made under section 8(3), 12(6) or 37(4) following an entitlement dispute. By completing part 7 you are requesting that this application takes the same filing date as an earlier UK application. If you want the new application to have the same priority date(s) as the earlier UK application, you should also complete part 6 with the priority details.

Ang 03

Patents Form 1/77

0098277-19-Mar-04 01:43

Prostate Stem Cell

5 The invention relates to a method for the isolation of prostate stem cells, typically prostate cancer stem cells; stem cells and cancer stem cells isolated by the method and their use.

10 The prostate gland is the major accessory organ of the male reproductive tract, and is the most common site of neoplastic disorders in men. The two main pathologies of the gland are: (i) benign prostatic hyperplasia, which is a non-malignant condition that is common with age and (ii) carcinoma, which is the second most common cause of death in European men, after lung cancer and is increasingly prevalent in our ageing Western Society. Symptoms include, blood in the semen or the urine, frequent pain or stiffness in the lower back, hips or upper thigh. Prostate tumours may be primary (i.e. located in the organ of origin) or secondary (i.e. tumours which form in
15 other organs due to the ability of cancerous cells to move and invade other tissues via the circulatory system).

Prostate cancer can be relatively harmless or extremely aggressive. Some prostate tumours are slow growing and cause few clinical symptoms. Aggressive prostate
20 tumours spread rapidly to the lymph nodes and other organs, especially bone. It is known that the growth of prostate cancer can be inhibited by blocking the supply of male hormones such as testosterone. However, prostate cancers eventually develop and become independent of male sex hormones (i.e. they become androgen-independent prostate cancer cells). These cells are linked with aggressive, malignant
25 prostate cancer. All male mammals have a prostate gland but only humans and dogs are known to naturally develop prostate cancer.

Metastatic prostate cancers predominantly move to the bone and are treated by reducing the production of androgens by blocking androgen production by the
30 adrenal glands and testis. This treatment is only effective for a short period of time as the metastatic lesions become androgen independent and grow uncontrollably.

The presence of androgen independent prostate cancer cells means that this treatment regime is no longer effective and further intervention is required to control the progress of the disease. A similar response is seen to chemotherapeutic and radiotherapy treatments. As a result, metastatic prostate cancer remains an incurable disease by current treatment strategies. There is therefore a continual need to identify new therapeutic targets to provide new treatments for prostate cancer.

A problem underlying the effective treatment of cancerous conditions is the identification of a population of cells in a tumour that have the ability of sustaining the growth of a tumour. The evidence suggests that tumours are clonal and are therefore derived from a single cell. However, there are few studies that identify and characterise those cells types that are responsible for maintaining tumour cell growth. Some have searched for these so called "cancer stem cells".

WO03/050502 discloses a method to selectively enrich breast tumour stem cells through the use of a xenograft model in which human breast cancer cells were grown in immunocompromised mice. WO03/102215 describes the isolation of stem cells and cancer stem cells by virtue of the specific expression of a reporter gene that is regulated by β catenin that becomes actively expressed in a stem cell. US2003119080 describes a method for the isolation of tumour stem cells from solid tumours. In WO0140309 is described antibodies to an alleged prostate stem cell antigen, referred to as prostate stem cell antigen (PSCA) which is also described in US5, 856, 136, WO99/14328 and WO98/51805, each of which is incorporated by reference.

We describe a method to selectively enrich for prostate stem cells or prostate cancer stem cells that utilises the differential adhesion to type I collagen and growth of stem cells in culture to select a population of cells with prostate stem cell potential.

We have identified CD133, which is expressed by primitive haematopoietic stem cells and developing epithelia as a further stem cell marker for prostate epithelia. CD133 cells are restricted to the $\alpha\beta_1^{hi}$ population (the receptor for type I collagen)

and are located in the basal layer, often at the base of a budding region or branching point (Appendix; Fig. 1A). $\alpha_2\beta_1^{hi}$ /CD133⁺ cells exhibit two important attributes of epithelial stem cells: they possess a high *in vitro* proliferative potential (Fig. 1B) and can reconstitute prostatic-like acini in immunocompromised male nude mice Fig. 5 1C).

Prostate tumour stem cells have been directly isolated from lymph node and prostate glands from a series of patient samples using the following markers: human epithelial antigen (HEA), CD44 (which is expressed by basal cells in the prostate; Liu et al., 10 1997), $\alpha_2\beta_1^{hi}$ and CD133. Morphologically the cells range from fibroblastoid (expressing high levels of vimentin which is typical of transformed cells) or epithelial, and are capable of producing progenitors associated with prostate epithelial differentiation (Fig. 2A). Invasion assays, using Matrigel-coated filters have determined that these cells have a similar capacity to invade through Matrigel 15 than PC3M (a highly metastatic subline of PC3 cells (Fig 2B)).

According to an aspect of the invention there is provided a method for the isolation of prostate stem cells comprising the selective enrichment of prostate cells which express CD133 antigen. Preferably said stem cells also express high levels of $\alpha_2\beta_1$ 20 integrin.

In a preferred method of the invention said selective enrichment comprises the following steps:

- i) providing a cell preparation comprising prostate cells derived from prostate tissue; 25
- ii) providing cell culture conditions which allow the maintenance of said prostate cells in culture and the binding of said prostate cells to a collagen based matrix;
- iii) selecting said bound cells wherein said cells express CD133 antigen. 30

In a preferred method of the invention said method includes the additional steps of:

- i) culturing cells which express CD133 antigen in culture medium comprising; granulocyte macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF) and leukaemia inhibitory factor (LIF); and
- 5 ii) passaging the selected cells in (i) in a serum free medium.

In a further preferred embodiment of the invention said selected cells express epithelial antigen, preferably human epithelial antigen.

- 10 In a yet further preferred method of the invention said selected cells express CD44 antigen.

In a preferred method of the invention said prostate derived tissue comprises cancerous prostate cells.

- 15 In a further preferred method of the invention said cancerous prostate cells are derived from malignant prostate derived tissue.

- 20 In a preferred method of the invention said cancerous prostate cells are derived from primary or metastatic lymph node sites.

In a further preferred method of the invention said collagen based matrix comprises collagen I.

- 25 According to a further aspect of the invention there is provided a prostate stem cell obtainable by the method according to the invention.

In a preferred embodiment of the invention said cell is a prostate cancer stem cell.

- 30 In a further preferred embodiment of the invention said stem cell is a cloned cell.

According to a further aspect of the invention there is provided a culture of prostate stem cells wherein said cells express CD133 antigen. Preferably said cells are prostate cancer stem cells.

- 5 In a preferred embodiment of the invention said cells express high levels of $\alpha_2\beta_1$ integrin.

In a further preferred embodiment of the invention said cells express human epithelial antigen. Preferably said cells express CD44 antigen.

10

In a yet further preferred embodiment of the invention said cells express CD133 antigen, high levels of $\alpha_2\beta_1$ integrin, human epithelial antigen and CD44 antigen.

15

Prostate stem cells/prostate cancer stem cells are typically characterised by specific phenotypic characteristics. For example, cells with stem cell potential are able to divide in culture in an undifferentiated state for multiple passages; able to form all the cell-types found in prostate tissue; and express gene markers of prostate stem cells and/or differentiated prostate cells. These characteristics are merely meant to be illustrative of prostate stem cells and not meant to be restrictive.

20

According to a further aspect of the invention there is provided a prostate stem cell preparation obtainable by the method according to the invention for use as in a vaccine composition.

25

It will be apparent that the prostate stem cells selected by the method according to the invention have utility with respect to the selection of genes expressed in normal prostate stem cells and also cancerous prostate stem cells. Antibodies generated to these expressed sequences are useful since they represent potential targets for the development of vaccines which may be used prophylactically or therapeutically to

30

treat those with a predisposition to prostate cancer or are suffering from either primary prostate cancer or from secondary prostate cancer as a result of metastasis

from a primary cancer. Antibodies generated will also have utility with respect to the diagnosis of prostate cancer.

5 In a preferred embodiment of the invention said prostate stem cell is a cancerous prostate stem cell.

According to a further aspect of the invention there is provided a vaccine composition comprising a prostate stem cell according to the invention.

10 In a preferred embodiment of the invention said composition includes and adjuvant and/or a carrier.

An adjuvant is a substance or procedure that augments specific immune responses to antigens by modulating the activity of immune cells. Examples of adjuvants include, 15 by example only, Freund's adjuvant, muramyl dipeptides, liposomes. A carrier is an immunogenic molecule which, when bound to a second molecule, augments immune responses to the latter. Some antigens are not intrinsically immunogenic yet may be capable of generating antibody responses when associated with a foreign protein molecule such as keyhole-limpet haemocyanin or tetanus toxoid. Such antigens 20 contain B-cell epitopes but no T cell epitopes. The protein moiety of such a conjugate (the "carrier" protein) provides T-cell epitopes which stimulate helper T-cells that in turn stimulate antigen-specific B-cells to differentiate into plasma cells and produce antibody against the antigen. Helper T-cells can also stimulate other immune cells such as cytotoxic T-cells, and a carrier can fulfil an analogous role in 25 generating cell-mediated immunity as well as antibodies.

According to a further aspect of the invention there is provided a method to immunise an animal comprising administering an effective amount of a prostate stem cell preparation according to the invention.

30

In a preferred method of the invention said cell preparation comprises cancerous prostate stem cells according to the invention.

In a preferred method of the invention said animal is a human.

In an alternative preferred method of the invention said animal is a rodent, preferably a rat, mouse or hamster.

In a further preferred method of the invention said animal is a rabbit, goat or sheep.

In a yet further preferred method of the invention said animal is a dog.

A preferred route of administration is intradermal, subcutaneous, intramuscular, oral or intranasal, however the immunisation method is not restricted to a particular mode of administration.

According to a further aspect of the invention there is provided an antibody obtainable by the method according to the invention.

In a preferred embodiment of the invention said antibody is a therapeutic antibody.

In a further preferred embodiment of the invention said antibody is a diagnostic antibody. Preferably said diagnostic antibody is provided with a label or tag.

In a preferred embodiment of the invention said antibody is a monoclonal antibody or binding fragment thereof. Preferably said antibody is a humanised or chimeric antibody.

A chimeric antibody is produced by recombinant methods to contain the variable region of an antibody with an invariant or constant region of a human antibody.

- A humanised antibody is produced by recombinant methods to combine the complementarity determining regions (CDRs) of an antibody with both the constant (C) regions and the framework regions from the variable (V) regions of a human antibody. Chimeric antibodies are recombinant antibodies in which all of the V-
- 5 regions of a mouse or rat antibody are combined with human antibody C-regions. Humanised antibodies are recombinant hybrid antibodies that fuse the complementarity determining regions from a rodent antibody V-region with the framework regions from the human antibody V-regions. The C-regions from the human antibody are also used. The complementarity determining regions (CDRs) are
- 10 the regions within the N-terminal domain of both the heavy and light chain of the antibody to where the majority of the variation of the V-region is restricted. These regions form loops at the surface of the antibody molecule. These loops provide the binding surface between the antibody and antigen.
- 15 Antibodies from non-human animals provoke an immune response to the foreign antibody and its removal from the circulation. Both chimeric and humanised antibodies have reduced antigenicity when injected to a human subject because there is a reduced amount of rodent (i.e. foreign) antibody within the recombinant hybrid antibody, while the human antibody regions do not elicit an immune response. This
- 20 results in a weaker immune response and a decrease in the clearance of the antibody. This is clearly desirable when using therapeutic antibodies in the treatment of human diseases. Humanised antibodies are designed to have less "foreign" antibody regions and are therefore thought to be less immunogenic than chimeric antibodies.
- 25 It is also possible to create single variable regions, so called single chain antibody variable region fragments (scFvs). If a hybridoma exists for a specific monoclonal antibody it is well within the knowledge of the skilled person to isolate scFvs from mRNA extracted from said hybridoma via RT PCR. Alternatively, phage display screening can be undertaken to identify clones expressing scFvs. Alternatively said
- 30 fragments are "domain antibody fragments". Domain antibodies are the smallest binding part of an antibody (approximately 13kDa). Examples of this technology is

disclosed in US6, 248, 516, US6, 291, 158, US6,127, 197 and EP0368684 which are all incorporated by reference in their entirety.

5 In a further preferred embodiment of the invention said antibodies are opsonic antibodies.

Phagocytosis is mediated by macrophages and polymorphic leukocytes and involves the ingestion and digestion of micro-organisms, damaged or dead cells, cell debris, insoluble particles and activated clotting factors. Opsonins are agents that facilitate the phagocytosis of the above foreign bodies. Opsonic antibodies are therefore 10 antibodies which provide the same function. Examples of opsonins are the Fc portion of an antibody or complement C3. Antibodies raised by immunisation and in the form of an immune complex with antigen may bring about opsonisation via the fixation of complement on the antigen, or molecules in its immediate 15 microenvironment.

According to a further aspect of the invention there is provided an antibody according to the invention for use as a pharmaceutical.

20 According to a further aspect of the invention there is provided a pharmaceutical composition comprising an antibody according to the invention.

According to a further aspect of the invention there is provided a T-lymphocyte obtainable by the method according to the invention.

25 Preferably said T-lymphocytes are T-helper lymphocytes.

The immune system is made up in part of lymphocytes which are able to recognise specific antigens. B lymphocytes recognise antigens in their native conformation 30 through surface immunoglobulin receptors, and T lymphocytes recognise protein antigens that are presented as peptides along with self molecules known as major

histocompatibility antigen (MHC), or human leukocyte antigen (HLA) in humans, on the surface of antigen presenting cells. Antigen presenting cells occur in different forms and may be distinguished into 'classical' antigen presenting cells, exemplified by macrophages and dendritic cells and 'non-classical' antigen presenting cells, which includes B lymphocytes. T lymphocytes may be further subdivided into "cytotoxic T lymphocytes", which are able to kill, for example virally infected target cells, and "T helper" lymphocytes. T helper lymphocytes have a regulatory function and are able to "help" B lymphocytes to produce specific antibody, or to help macrophages to kill cancer cells.

10

According to a further aspect of the invention there is provided a method for the identification of genes associated with prostate stem cells comprising the steps of:

- i) providing a preparation comprising at least one prostate stem cell according to the invention;
- 15 ii) extracting nucleic acid from said cell preparation;
- iii) contacting said extracted nucleic acid with a nucleic acid array; and
- iv) detecting a signal which indicates the binding of said nucleic acid to a binding partner on said nucleic acid array.

20 Preferably said method includes the additional steps of:

- i) collating the signal(s) generated by the binding of said nucleic acid to said binding partner;
- ii) converting the collated signal(s) into a data analysable form; and optionally;
- 25 iii) providing an output for the analysed data.

In a preferred method of the invention said preparation comprises cancer prostate stem cells.

30 In a further preferred method of the invention said method includes a comparison of the array signal produced between normal and cancer prostate stem cells.

In an alternative preferred method of the invention said method includes a comparison of the array signal produced between a first cancer prostate stem cell sample and a second, different cancer prostate stem cell sample.

5

According to a further aspect of the invention there is provided a method for the preparation of a library comprising prostate specific gene expression products comprising the steps:

- 10 i) providing a preparation comprising at least one prostate stem cell according to the invention;
- ii) extracting nucleic acid from said cell preparation;
- iii) preparing a cDNA from ribonucleic acid contained in said extracted nucleic acid; and
- 15 iv) ligating cDNA formed in (iii) into a vector.

In a preferred method of the invention said vector is a phage based vector.

In our PCT application, WO03/014334 we have developed an *in vitro* cell culture method which provides a culture regime that allows prostate epithelial cells to form prostate-like-acini which closely resemble prostate acini found *in vivo*. The method relies on a combination of serum, hormones and a suitable cell matrix support which allows the epithelial cells to attach, proliferate, differentiate and form prostatic-like-acini. The system is able to support growth of cloned normal prostate epithelial cells as well as cloned cancerous prostate cells, primary prostate epithelial cells and primary cancerous prostate cells to provide a 3D structure which reflects the *in vivo* state. The system is invaluable for the study of prostate cell differentiation and prostate cell transformation. It will provide a tool for use in the identification of agents effective at inhibiting the proliferation and metastasis of prostate cancer cells and also to identify novel markers of prostate cell differentiation and transformation. We disclose herein that prostate stem cells selected by the method according to the

invention are able to form prostate-like acini as described in WO03/014334, which is incorporated by reference in its entirety.

5 According to an aspect of the invention, there is provided an *in vitro* method for the formation of prostate-like acini comprising:

- i) providing a cell culture vessel comprising:
 - a) prostate stem cells according to the invention;
 - b) a cell culture support matrix to which the cells in (a) can attach and proliferate;
 - 10 c) cell culture medium supplemented with serum, a stromal fraction and a ratio of the hormones oestrogen and dihydrotestosterone, or functional derivatives thereof; and
- ii) providing conditions which promote the growth and differentiation of said prostate derived cells in said vessel.

15

According to a further aspect of the invention there is provided an *in vitro* method for the formation of vascularised prostate acini comprising the steps of:

- i) providing a cell culture vessel which includes: prostate-like acini formed from prostate stem cells according to the invention that have been formed in a cell culture medium supplemented with serum, a stromal fraction, and a ratio of oestrogen and dihydrotestosterone, or functional derivatives thereof, a cell culture support matrix; and a cell culture medium which supports the growth of said prostate acini; and
- 20 ii) addition of activated endothelial cells to said cell culture vessel wherein said endothelial cells proliferate and/or migrate to form blood vessel tubules in or around said acini.

25

According to an aspect of the invention, there is provided an *in vitro* method for the formation of vascularised prostate-like acini comprising:

- 30 i) providing a cell culture vessel which includes:

- a) prostate stem cells and activated endothelial cells;
- b) a cell culture support matrix to which the cells in (a) can attach and proliferate;
- c) cell culture medium supplemented with serum, a stromal fraction and a ratio of the hormones oestrogen and dihydrotestosterone, or functional derivatives thereof; and
- 5 ii) providing conditions which promote the growth and differentiation of said prostate stem cells in said vessel to form prostate acini and the vascularisation of said acini by the formation of blood vessel tubules from said activated endothelial
- 10 cells.

In a preferred method of the invention said prostate epithelial cells and endothelial cells are of human origin.

- 15 "Vessel" is defined as any means suitable to contain the above described cell culture. Typically, examples of such a vessel is a petri dish; cell culture bottle or flask; multiwell culture dishes.

- 20 According to a further aspect of the invention there is provided a prostate-like acinus obtainable by the method according to the invention.

In a preferred embodiment of the invention said prostate-like acinus comprises genetically engineered prostate cells.

- 25 Genetic engineering may be undertaken to introduce a gene or genes into a stem cell from which an acinus can then be formed. For example, and not by way of limitation, pro-drug activating genes may be transfected into prostatic cells to monitor the efficacy of pro-drugs as cytotoxic agents. A pro-drug activating gene refers to a gene the expression of which results in the production of protein capable
- 30 of converting a non-therapeutic compound into a therapeutic compound, which

renders the cell susceptible to killing by external factors or causes a toxic condition in the cell.

- An example of a prodrug activating gene is the cytosine deaminase gene. Cytosine deaminase converts 5-fluorocytosine to 5-fluorouracil, a potent antitumor agent. The
- 5 lysis of the tumor cell provides a localized burst of cytosine deaminase capable of converting 5FC to 5FU at the localized point of the tumor resulting in the killing of many surrounding tumour cells. This results in the killing of a large number of tumor cells without the necessity of infecting these cells with a vector (the so-called "bystander effect"). Another example of a prodrug-activating gene is thymidine
- 10 kinase (TK) (see US5,631,236 and US 5,601,818) in which the cells expressing the TK gene product are susceptible to selective killing by the administration of gancyclovir. This is merely meant to be illustrative of recombinant methods which could be used in combination with the cells according to the invention. Other examples may include the transfection of tumour suppressor genes, (e.g. p53). The
- 15 term tumour suppressor gene refers to a nucleotide sequence, the expression of which in a target cell is capable of suppressing the cancerous phenotype and/or inducing apoptosis.

- According to a further aspect of the invention there is provided a method to identify
- 20 agents capable of inhibiting the proliferation of cancerous prostatic cells comprising:
- i) providing culture conditions and at least one cancerous acinus according to the invention;
 - ii) adding at least one agent to be tested; and
 - iii) monitoring the anti-proliferative activity of the agent with respect to the cells
- 25 comprising the cancerous acinus.

- According to a yet further aspect of the invention there is provided a method to identify agents capable of inhibiting the motility of cancerous prostatic cells comprising:
- 30 i) providing culture conditions and at least one cancerous acinus according to the invention;

- ii) adding at least one agent to be tested; and
- iii) monitoring the motility of cells comprising the cancerous acinus.

According to a further aspect of the invention there is provided a method to identify
5 markers of prostate cell differentiation comprising the steps:

- i) providing a preparation comprising prostate stem cells according to the invention; and
- ii) determining the expression of at least one gene the expression of which is associated with the differentiation of prostate cells.

10

According to a further aspect of the invention there is provided a method to identify
markers of prostate cell transformation

- i) providing a preparation comprising prostate stem cells according to the invention; and
- 15 ii) determining the expression of at least one gene the expression of which is associated with the transformation of prostate cells.

Methods used in the identification of cell differentiation markers and/or markers of
prostate cell transformation include immunogenic based techniques (eg using the
20 cells as complex immunogens to develop antisera to cell surface markers as described
above and the like) nucleic acid based techniques (eg differential screening using
cDNA from normal and transformed acini). Also, it has been known for many years
that tumour cells produce a number of tumour cell specific antigens, some of which
are presented at the tumour cell surface. These are generally referred to as tumour
25 rejection antigens and are derived from larger polypeptides referred to as tumour
rejection antigen precursors. Tumour rejection antigens are presented via HLA's to
the immune system. The immune system recognises these molecules as foreign and
naturally selects and destroys cells expressing these antigens. If a transformed cell
escapes detection and becomes established a tumour develops. Vaccines have been
30 developed based on dominant tumour rejection antigens to provide individuals with a
preformed defence to the establishment of a tumour. The method according to the

invention provides a means to identify tumour rejection antigens and precursors which will have utility with respect to vaccine development to provoke the patients own immune system to deter the establishment of prostate tumours.

- 5 An embodiment of the invention will now be described by example only and with reference to the following Figures:

Figure 1: Verification of CD133 as a stem cell marker of prostatic epithelia: 1A: A paraffin section of prostatic acini labelled with the nuclear stain DAPI (Blue) and anti-CD133 directly conjugated to PE (Red). 1B: Basal cells with the phenotype $\alpha_2\beta_1^{hi}/CD133^+$ have a higher colony forming efficiency (CFE) than $\alpha_2\beta_1^{low}/CD133^-$. (CFE) was calculated as the number of colonies formed per number of selected cells $\times 100\%$. CFEs are expressed as the ratio of the control CFE. Results show means \pm s.e.m of four experiments. 1C. Xenografts of prostate acini formed by transplantation of $\alpha_2\beta_1^{hi}/CD133^+$ basal cells stained with (A) Haematoxylin and Eosin, (B) 34 β E12, (C) anti-K18, (D) anti-PAP (E) Anti-androgen receptor. Bar 40 μ m; and

Figure 2: Characterisation of tumour 'stem' cells from a lymph node metastasis of the prostate (LNMP). 2A. Tumour cells selected on the basis of $\alpha_2\beta_1/CD133$ differentiate in culture. 2B. Invasion assay activity of LNMP in comparison to PC3M and an immortalised prostate epithelial cell line, PNT1a.

Materials and Methods

25 Genotype of isolated tumour stem cells

Using a combination of microsatellite markers associated with sporadic prostate cancer (8p 10q 16p, Fig 3) we can determine whether the isolated HEA $^+$ /CD44 $^+$ / $\alpha_2\beta_1^{hi}/CD133^+$ cells display loss of heterozygosity patterns characteristic of prostate tumours in comparison to blood lymphocyte DNA from the same patient. The analysis is carried out on a microsampling of cultures with 3MM paper and fluorescently labelled PCR primers (MacIntosh et al., 1998). This will

enable us to discriminate between normal and cancer cells and determine whether stem cells are indeed targets for transforming events.

5 **Proliferative, differentiative and malignant potential of putative cancer stem cells**

Distinct populations of tumour cells are isolated and their proliferative, differentiative and malignant potential determined *in vitro* and *in vivo*. The following populations (HEA⁺/CD44⁻ (luminal cells), HEA⁺/CD44⁺ (basal cells),
10 HEA⁺/CD44⁺/α₂β₁^{low}/CD133⁻ (transit cells), HEA⁺/CD44⁺/α₂β₁^{hi}/CD133⁺ (stem cells)) are isolated and compared with the unsorted tumour population.

15 **Colony forming efficiency (CFE): anchorage independent and anchorage-dependent growth**

The transforming potential of distinct populations (as above) of cancer cells (anchorage independence) are measured by their ability to form colonies in soft agar. Individual colonies are counted after 21 days using an inverted microscope. Comparisons are made of CFE and colony size.

20 **Morphogenesis in gels of reconstituted basement membrane matrix**

We have determined the potential of tumour stem cells and their progenitors to undergo glandular morphogenesis in reconstituted basement membrane (e.g.
25 Matrigel). We have demonstrated that normal basal cells can undergo glandular morphogenesis when grown in a collagen based matrix, (e.g. Matrigel) with stroma, in the presence of androgens. Spheroids are generated which are architecturally and phenotypically similar to *in vivo* acini and are often branched alveolar and duct like (Lang *et al.*, 2001). In contrast, cancer cells often form large aggregates of spindle-
30 shaped cells with no obvious organisation. Nonetheless, the structures will often contain cells that show some degree of differentiation and can be compared to the original tumour.

Invasion assays

The ability of these stem cells to migrate across Matrigel is determined by the modified Boyden-chamber method (Albini *et al.*, 1987). Migration rates will be evaluated using time-lapse confocal microscopy, using cells labelled with EGFP. We have generated prostate epithelium expressing low levels of EGFP. Recombinant retrovirus based on pLNCX-EGFP(2) generated will be used to infect the cell populations and G418 resistant colonies will be used in motility assays. The low levels of GFP expression will be used to track invasion and motility in real time.

10

In vivo tumourigenesis

Tumour stem cells must possess key criteria that define normal stem cells: after transplantation they must proliferate, differentiate and self-renew. To determine the ability of distinct tumour phenotypes, to colonise *in vivo*, grafts of stem cells, transit cells, basal cells, luminal cells and unsorted cells are introduced into the prostates of 6 to 8 week old male, immunocompromised mice. The mice are treated hormonally at the time of grafting by subcutaneous implantation of sustained release testosterone pellets. The number of cells from each population that successfully engraft and initiate tumour proliferation is determined by varying the number of cells implanted. The self-renewal capacity of the distinct populations are determined by transplanting serially into secondary recipients.

25

Comparison of gene expression profiles between cancer and normal stem cells

Expression profiles are obtained from stem cells isolated from cancer containing and non-cancer tissue samples. An Affymetrix GeneChip microarray platform is used to assay the absolute gene expression levels for each sample. To accomplish this, total RNA is extracted from purified $\alpha_2\beta_1^{+}$ cells. As the cell yield is low it is necessary to use a linear amplification step to provide sufficient target for hybridisation to the

30

arrays. The Affymetrix small sample labelling protocol has been demonstrated to work well with 100ng (~10³ cells) but can be used for as little as 1-10ng total RNA. To date we have used this technology (Hu-U133A GeneChips) to profile amplified total RNA extracted from selected cell populations (including $\alpha_2\beta_1^{++}$) derived from
5 our recently isolated prostate cancer lymph node metastasis cell line.

Each sample is derived from a separate individual therefore, a substantial degree of variation in gene expression (both between cancer and non-cancer samples and between samples within the same class) will be due to the underlying genetic
10 heterogeneity between the individuals. As a result it is necessary to include a number of 'biological' replicates within each class of sample and we typically use 6-10 samples for each (i.e. up to 20 samples in total).

Batch comparison analysis is used to compare each cancer sample experiment to each
15 of the non-cancer samples and subject the comparisons to three different statistical algorithms, based on the Mann-Whitney test, non-parametric Wilcoxon rank test and self-organising map cluster analysis, to detect differential expression. Furthermore, we apply cluster analysis to look for groups of genes which behave differently from the norm.

20

25

Claims

1. A method for the isolation of prostate stem cells comprising the selective enrichment of prostate cells which express CD133 antigen.
5
2. A method according to Claim 1 wherein said stem cells also express high levels of $\alpha_2\beta_1$ integrin.
3. A method according to Claim 1 or 2 wherein said selective enrichment
10 comprises the following steps:
 - i) providing a cell preparation comprising prostate cells derived from prostate tissue;
 - ii) providing cell culture conditions which allow the maintenance of said prostate cells in culture and the binding of said prostate cells to a
15 collagen based matrix;
 - iii) selecting said bound cells wherein said cells express CD133 antigen.
4. A method according to Claim 3 wherein said method includes the additional steps of:
20
 - i) culturing cells which express CD133 antigen in culture medium comprising granulocyte macrophage colony stimulating factor (GM-CSF), stem cell factor (SCF) and leukaemia inhibitory factor (LIF); and
 - ii) passaging the selected cells in (i) in a serum free medium.
25
5. A method according to any of Claims 1-4 wherein said selected cells express epithelial antigen.
6. A method according to Claim 5 wherein said antigen is human epithelial
30 antigen.

7. A method according to any of Claims 1-6 wherein said selected cells express CD44 antigen.
8. A method according to any of Claims 1-7 wherein said prostate derived tissue comprises cancerous prostate cells.
9. A method according to Claim 8 wherein said cancerous prostate cells are derived from metastatic prostate derived tissue.
10. A method according to Claim 9 wherein said cells are derived from primary and metastatic prostate tumours.
11. A method according to any of Claims 1-10 wherein said collagen based matrix comprises collagen I.
12. A prostate stem cell obtainable by the method according to any of Claims 1-11.
13. A prostate stem cell according to Claim 12 wherein said cell is a prostate cancer stem cell.
14. A prostate stem cell according to Claim 13 wherein said stem cell is cloned.
15. A cell culture of prostate stem cells wherein said cells express CD133 antigen.
16. A culture according to Claim 15 wherein said cloned cells are prostate cancer stem cells.
17. A culture according to Claim 16 wherein said cells express high levels of $\alpha_2\beta_1$ integrin.

- 18 A culture according to Claim 16 or 17 wherein said cells express epithelial antigen.
- 5 19. A culture according to Claim 18 wherein said epithelial antigen is human epithelial antigen.
20. A culture according to any of Claims 16-19 wherein cells express CD44 antigen.
- 10 21. A culture according to Claim 16 wherein said cells express CD133 antigen, high levels of $\alpha_2\beta_1$ integrin, human epithelial antigen and CD44 antigen.
- 15 22. A prostate stem cell preparation obtainable by the method according to any of Claims 1-11 for use as in a vaccine composition.
23. A preparation according to Claim 22 wherein said prostate stem cells are cancerous prostate stem cells.
- 20 24. A vaccine composition comprising a prostate stem cell culture according to any of Claims 15-21.
- 25 25. A composition according to Claim 24 wherein said composition includes an adjuvant and/or a carrier.
26. A method to immunise an animal comprising administering an effective amount of a prostate stem cell culture according to any of Claims 15-21.
- 30 27. A method according to Claim 26 wherein said cell culture comprises cancerous prostate stem cells.

28. A method according to Claim 26 or 27 wherein said animal is a human.
29. A method according to Claim 26 or 27 wherein said animal is a rodent.
- 5 30. A method according to Claim 26 or 27 wherein said animal is a rabbit, goat or sheep.
31. A method according to Claim 26 or 27 wherein said animal is a dog.
- 10 32. An antibody obtainable by the method according to any of Claims 26-31.
33. An antibody according to Claim 32 wherein said antibody is a monoclonal antibody or binding fragment thereof.
- 15 34. An antibody according to Claim 32 or 33 for use as a pharmaceutical.
35. A pharmaceutical composition comprising an antibody according to Claim 32 or 33.
- 20 36. A T-lymphocyte obtainable by the method according to any of Claims 26-31.
37. A T-lymphocytes according to Claim 36 wherein said lymphocytes are T-helper lymphocytes.
- 25 38. A method for the identification of genes that show enhanced expression in prostate stem cells comprising the steps of:
- i) providing a preparation comprising at least one prostate stem cell according to the invention;
 - ii) extracting nucleic acid from said cell preparation;
 - 30 iii) contacting said extracted nucleic acid with a nucleic acid array; and

iv) detecting a signal which indicates the binding of said nucleic acid to a binding partner on said nucleic acid array.

39. A method according to Claim 38 wherein said method includes the additional
5 steps of:

- i) collating the signal(s) generated by the binding of said nucleic acid to said binding partner;
- ii) converting the collated signal(s) into a data analysable form; and optionally;
- 10 iii) providing an output for the analysed data.

40. A method according to Claim 38 or 39 wherein said preparation comprises cancer prostate stem cells.

15 41. A method according to any of Claims 38-40 wherein said method includes a comparison of the array signal produced between normal and cancer prostate stem cells.

42. A method according to any of Claims 38-40 wherein said method includes a
20 comparison of the array signal produced between a first cancer prostate stem cell sample and a second, different, cancer prostate stem cell sample.

43. A method for the preparation of a library comprising prostate specific gene expression products comprising the steps:

- 25 i) providing a preparation comprising at least one prostate stem cell according to any of Claims 12-14;
- ii) extracting nucleic acid from said cell preparation;
- iii) preparing a cDNA from ribonucleic acid contained in said extracted nucleic acid; and
- 30 iv) ligating cDNA formed in (iii) into a vector.

44. A method according to Claim 43 wherein said vector is a phage based vector.

45. An *in vitro* method for the formation of prostate-like acini comprising:

- 5 i) providing a cell culture vessel comprising:
- a) prostate stem cells according to any of Claims 12-14;
 - b) a cell culture support matrix to which the cells in (a) can attach and proliferate;
 - 10 c) cell culture medium supplemented with serum, a stromal fraction and a ratio of the hormones oestrogen and dihydrotestosterone, or functional derivatives thereof; and
- ii) providing conditions which promote the growth and differentiation of said prostate derived cells in said vessel.

15 46. A prostate-like acinus obtainable by the method according to Claim 45.

47. A cancerous prostate-like acinus obtainable by the method according to Claim 45.

20 48. A prostate-like acinus according to Claim 46 or 47 wherein said acinus comprises genetically engineered prostate cells.

25 49. A method to identify agents capable of inhibiting the proliferation of cancerous prostatic cells comprising:

- i) providing culture conditions and at least one cancerous acinus according to Claim 47 or 48;
- ii) adding at least one agent to be tested; and
- 30 iii) monitoring the anti-proliferative activity of the agent with respect to the cells comprising the cancerous acinus.

50. A method to identify agents capable of inhibiting the motility of cancerous prostatic cells comprising:

- 5
- i) providing culture conditions and at least one cancerous acinus according to Claim 47 or 48;
 - ii) adding at least one agent to be tested; and
 - iii) monitoring the motility of cells comprising the cancerous acinus.

10 51. A method to identify markers of prostate cell differentiation comprising the steps:

- 15
- i) providing a preparation comprising prostate stem cells according to any of Claims 12-14; and
 - ii) determining the expression of at least one gene the expression of which is associated with the differentiation of prostate cells.

52. A method to identify markers of prostate cell transformation

- 20
- i) providing a preparation comprising prostate stem cells according to any of Claims 12-14; and
 - ii) determining the expression of at least one gene the expression of which is associated with the transformation of prostate cells.

25 53. An *in vitro* method for the formation of vascularised prostate acini comprising the steps of:

- 30
- i) providing a cell culture vessel which includes: prostate-like acini formed from prostate stem cells according to the invention that have been formed in a cell culture medium supplemented with serum, a stromal fraction, and a ratio of oestrogen and dihydrotestosterone, or functional derivatives thereof, a cell culture support matrix; and a cell culture medium which supports the growth of said prostate acini; and

- ii) addition of activated endothelial cells to said cell culture vessel wherein said endothelial cells proliferate and/or migrate to form blood vessel tubules in or around said acini.

5 54. An *in vitro* method for the formation of vascularised prostate-like acini comprising:

i) providing a cell culture vessel which includes:

- a) prostate stem cells and activated endothelial cells;
b) a cell culture support matrix to which the cells in (a) can attach
10 and proliferate;

c) cell culture medium supplemented with serum, a stromal fraction and a ratio of the hormones oestrogen and dihydrotestosterone, or functional derivatives thereof; and

15 ii) providing conditions which promote the growth and differentiation of said prostate epithelial cells in said vessel to form prostate acini and the vascularisation of said acini by the formation of blood vessel tubules from said activated endothelial cells.

20 55. A method according to Claim 53 or 54 wherein said prostate stem cells and endothelial cells are of human origin.

25

30

35

Abstract

- 5 We describe a method for the isolation of prostate stem cells, typically prostate cancer stem cells which express CD133 antigen; stem cells and cancer stem cells isolated by the method and their use.

2A


Vimentin




Cytokeratin 18



E-Cadherin



PSA



2B




Figure 2: Characterisation of tumour 'stem' cells from a lymph node metastasis of the prostate (LNMP). 2A. Tumour cells selected on the basis of $\alpha_2\beta_1$ /CD133 differentiate in culture. **2B.** Invasion assay activity of LNMP in comparison to PC3M and an immortalised prostate epithelial cell line, PNT1a.




Figure 1: Verification of CD133 as a stem cell marker of prostatic epithelia: 1A: A paraffin section of prostatic acini labelled with the nuclear stain DAPI (Blue) and anti-CD133 directly conjugated to PE (Red). 1B: Basal cells with the phenotype $\alpha_2\beta_1^{\text{hi}}/\text{CD133}^+$ have a higher colony forming efficiency (CFE) than $\alpha_2\beta_1^{\text{low}}/\text{CD133}^+$. (CFE) was calculated as the number of colonies formed per number of selected cells $\times 100\%$. CFEs are expressed as the ratio of the control CFE. Results show means \pm s.e.m of four experiments. 1C. Xenografts of prostate acini formed by transplantation of $\alpha_2\beta_1^{\text{hi}}/\text{CD133}^+$ basal cells stained with (A) Haematoxylin and Eosin, (B) 34 β E12, (C) anti-K18, (D) anti-PAP (E) Anti-androgen receptor. Bar 40 μm .